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Abstract
Recent studies indicate high density lipoproteins (HDL) and their major structural protein,
apolipoprotein A1 (apoA1), recovered from human atheroma, are dysfunctional and extensively
oxidized by myeloperoxidase (MPO), while in vitro oxidation of apoA1/HDL by MPO impairs its
cholesterol acceptor function. We developed a high affinity monoclonal antibody (mAb) that
specifically recognizes apoA1/HDL modified by the MPO/H2O2/Cl-system using phage display
affinity maturation. An oxindolyl alanine (2-OH-Trp) moiety at tryptophan 72 of apoA1 is the
immunogenic epitope. Mutagenesis studies confirm a critical role for apoA1 Trp72 in MPOmediated inhibition of ABCA1-dependent cholesterol acceptor activity of apoA1 in vitro and in
vivo. ApoA1 containing a 2-OH-Trp72 group (oxTrp72-apoA1) is in low abundance within the
circulation, but accounts for 20% of the apoA1 in atherosclerotic plaque. OxTrp72-apoA1
recovered from human atheroma or plasma was lipid-poor, virtually devoid of cholesterol acceptor
activity, and demonstrated both potent pro-inflammatory activities on endothelial cells and
impaired HDL biogenesis activity in vivo. Elevated oxTrp72-apoA1 levels in subjects presenting to
a cardiology clinic (n=627) were associated with increased cardiovascular disease risk. Circulating
oxTrp72-apoA1 levels may serve as a way to monitor a pro-atherogenic process in the artery wall.

Introduction
High density lipoprotein (HDL) is a complex and heterogeneous assembly of proteins and
lipids. Defined by its buoyant density isolation characteristics, its compositional
heterogeneity mirrors its functional heterogeneity, which includes cholesterol acceptor
activity, anti-inflammatory, anti-apoptotic, anti-thrombotic, microRNA delivery, and innate
immune functions1–6. Approximately 75% of the protein content of HDL is apolipoprotein
A1 (apoA1), which serves as the primary protein scaffolding upon which the lipid cargocarrying particle is built. The majority of apoA1 within the circulation is associated with
HDL, which contains two or more apoA1, depending upon both the degree of particle
maturation and the protein complement associated with a given HDL particle. Epidemiology
studies show an inverse association between circulating HDL cholesterol (HDLc) or apoA1
levels and coronary artery disease (CAD)7. Animal studies using both genetic and direct
infusion models similarly show global anti-atherosclerotic functions of the lipoprotein8–12.
Recent clinical studies, however, reveal significant gaps in our knowledge about HDL. For
example, while several clinical intervention studies employing either direct infusion of HDL
forms or infusion of extracorporeal delipidated HDL/apoA1 have shown evidence of antiatherosclerotic effects13–15, several distinct classes of HDL cholesterol-elevating drugs
have, in contrast, failed to demonstrate significant therapeutic benefit16–18. Moreover,
genetic studies demonstrate genetic variants that influence total circulating HDLc levels are
not mechanistically linked to CAD development19. Taken as a whole, recent studies
underscore the complexity and evolving understanding of the relationship between
circulating levels of HDLc and/or apoA1 and CAD pathogenesis.
One possible explanation of the paradox between observed associations between HDLc
levels and reduced CAD risks, versus the negative outcomes of recent therapeutic
intervention studies targeting HDLc levels, is that a function of the HDL particle, and not
the HDLc mass itself, is more clinically relevant diagnostically and therapeutically. For
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example, measurement of cholesterol efflux activity of HDL, or apolipoprotein-B depleted
serum, may serve as a superior independent predictor of prevalent CAD risk compared to
HDLc4. Moreover, alternative functional measures of HDL or its associated proteins may
provide improved clinical value and prognostic efficacy5,20–24. Furthermore, current
measures of HDL mass (either HDLc or apoA1) in the circulation do not appear to
adequately reflect the pathobiology of a diseased artery wall. Recent studies of total apoA1
(both HDL-associated and lipid-poor forms) from human aortic tissues revealed the
biological function and HDL particle distribution of apoA1 within the artery wall is
markedly distinct from that of circulating apoA1 and HDL. Specifically, apoA1 in human
aorta was found to be predominantly lipid-poor, not associated with HDL, extensively
oxidatively cross-linked, and functionally impaired25. ApoA1 serves as a selective target
(100–500 fold) for oxidative modification by MPO-generated and NO-derived oxidants
within the artery wall, resulting in site-specific oxidative modifications26–28. Parallel in vitro
studies have shown marked reductions in ATP-binding cassette transporter A1 (ABCA1)dependent cholesterol efflux function, lecithin cholesterol acyl transferase (LCAT) activity,
lipid binding activity, and non-cholesterol related activities (e.g. anti-apoptotic, antiinflammatory) in either HDL or apoA1 oxidized ex vivo by the MPO/H2O2/Cl- system to an
extent similar to that observed in apoA1 recovered from human lesions26,28–30. These
findings, and studies demonstrating pro-inflammatory activities for HDL recovered from
subjects with CAD or chronic inflammatory conditions associated with CAD risk21,31–33,
suggest that the molecular processes that impair apoA1/HDL function in the artery wall may
be diagnostic and therapeutic targets for CAD.
Herein we report tryptophan 72 of apoA1 serves as a selective target for MPO-dependent
oxidative modification forming an oxindolyl alanine (2-hydroxy-L-trytophan, 2-OH-Trp;
IUPAC name 2-amino-3-(2-oxo-1,3-dihydroindol-3-yl)propanoic acid) moiety on 20% of
apoA1 recovered from human atherosclerotic lesions. Functional characterization studies of
lesion and plasma apoA1 harboring this site-specific modification reveals a dysfunctional
apolipoprotein with both significantly impaired cholesterol efflux acceptor activity and proinflammatory function. Moreover, clinical studies indicate levels of this dysfunctional
apoA1 form within the circulation reflect a presumed pathophysiological process within the
artery wall.

Results
Development of antibody specific for MPO-modified apoA1
Direct studies of HDL function in the human artery wall to date have been limited. In order
to recover and study the chemical modifications and biological activities of HDL modified
by MPO-generated oxidants in the artery wall, we sought to develop immunological tools to
specifically detect and immunopurify apoA1 modified by the MPO/H2O2/Cl− system. This
specific oxidized form of apoA1/HDL was selected since in vitro studies demonstrate this
pathway readily inhibits cholesterol acceptor activity of both apoA1 and HDL under
pathophysiologically plausible conditions26–27,29. Over 30,000 hybridoma cell lines were
generated and screened after immunizing BALB/c mice with native reconstituted HDL
particles (apoA1:POPC:cholesterol, 1:100:10, mol:mol:mol) exposed to either MPO-
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generated chlorinating oxidants (the MPO/H2O2/Cl− system), or MPO-generated nitrating
oxidants (the MPO/H2O2/NO2− system) (Supplementary Fig. 1a). To ensure potential
epitopes formed on the antigens would be those likely formed under (patho)physiologically
plausible conditions, a low molar ratio of H2O2:apoA1 was used (5:1) and the content of
protein-bound 3-chlorotyrosine or 3-nitrotyrosine were determined and shown to be within
the range previously observed on apoA1 recovered from human atherosclerotic plaque26,29.
A monoclonal antibody (mAb) was identified (clone 8B5.2) that specifically recognized
both apoA1 and HDL exposed to the MPO/H2O2/Cl− system, but not apoA1 or HDL in their
native (unoxidized) forms, or following exposure to alternative oxidant systems including
the MPO/H2O2/NO2− oxidant system (Supplementary Fig. 1a).
While mAb 8B5.2 had the desired specificity, its affinity proved to be too low for either
efficient immunoprecipitation or use in an ELISA format to detect endogenous circulating
levels of oxTrp72-apoA1 (Supplementary Fig. 1b–d). We used phage display technology to
affinity mature (as single chain antibody) mAb 8B5.2 and then after sequencing gain of
function mutants, we genetically engineered the recombinant IgG form as described under
Methods. Briefly, human apoA1 exposed to the MPO/H2O2/Cl− system was used as positive
selection bait. Native human apoA1 and human apoA1 exposed to MPO-generated nitrating
oxidants (see Methods) were both used as negative selection bait after the first round
selection. During the last 2 affinity maturation cycles, multiple gain of function subclones
were sequenced and reproducible gain of function mutations identified. All gain of function
mutants were then incorporated into a single clone and verified to be functional as a high
affinity binder with appropriate specificity. This “combined” gain of function clone was then
converted into a chimeric humanized double chain IgG mAb (Fig. 1a–c). We termed this
affinity-matured recombinant humanized mAb r8B5.2, which displayed a 1,600-fold
enhanced affinity compared to the starting (parental) mAb, attaining a KD of 1 × 10−10 M
(Supplementary Fig. 1c). More detailed characterization studies confirmed the recombinant
affinity-matured antibody (mAb r8B5.2) retained exclusive specificity for recognition of
apoA1 exposed to the MPO/H2O2/Cl− system (Fig. 1d). Further characterization of mAb
r8B5.2 revealed it had sufficient affinity to immunoprecipitate MPO-oxidized apoA1, and
when used in ELISA format, had adequate sensitivity to detect and quantify apoA1/HDL
following oxidation by the MPO/H2O2/Cl− system at levels of oxidation comparable to
those observed in plasma or serum (Supplementary Fig. 1d).
MPO oxidation of apoA1 Trp72 inhibits cholesterol acceptor function
No studies to date have directly examined the functional significance of MPO modification
of apoA1 or HDL within human atheroma. Rather, the proposed role for MPO-catalyzed
oxidation of apoA1/HDL in impairing cholesterol acceptor activity of the lipoprotein in vivo
is based upon correlative data comparing the degree of oxidative modifications on apoA1
recovered from artery wall tissues, with both the extent of oxidative modifications formed
and the degree of ABCA1-dependent cholesterol efflux impairment observed in model
systems ex vivo26,29. Incubation of apoA1 or HDL with the MPO/H2O2/Cl− system can
promote oxidative modification of multiple oxidant sensitive residues, including (but not
limited to) each of the three Met, each of the seven Tyr, and each of the four Trp. Oxidation
of each of these residues has been detected by proteomics analysis of apoA1 or HDL
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recovered from human atherosclerotic lesions, yet debate exists about the relative abundance
of various species and their functional importance26–29,34. We hypothesized that the epitope
recognized by mAb r8B5.2 might be an oxidized form of Tyr, Met or Trp resulting from the
MPO/H2O2/Cl− system within the appropriate sequence context of apoA1. To test this, we
generated recombinant mutant forms of apoA1 in which each of these residues was
converted to a relatively non-oxidizable alternative amino acid of similar size and chemical
properties – namely: (i) each of the 7 Tyr residues (positions 18,29,100,115,166,192 and
236) were mutated to the relatively non-oxidizable Phe residue (mutant named “7YF”); (ii)
each of the 3 Met residues (positions 86,112 and 148) were mutated to the relatively nonoxidizable Val residue (mutant named “3MV”); and (iii) each of the 4 Trp residues
(positions 8,50,72 and 108) were mutated to the relatively non-oxidizable Phe residue
(mutant named “4WF”). We reasoned that following exposure of the lipoprotein to the
MPO/H2O2/Cl− system, the mutant form of apoA1 no longer harboring the oxidant resistant
residue, should not be recognized by mAb r8B5.2, whereas recombinant human (wild type
sequence) apoA1 (rh-apoA1), would be recognized following oxidation. Exposure of rhapoA1, 7YF and 3MV to the MPO/H2O2/Cl− system produced an oxidized apolipoprotein
recognized by mAb r8B5.2; whereas apoA1 mutant 4WF was not recognized following
oxidation (Fig. 2a). Importantly, control studies showed that all apoA1 mutant forms
examined retained cholesterol efflux activity in their native form, and all but 4WF lost
ABCA1-dependent and total cholesterol efflux activities following exposure to the
MPO/H2O2/Cl− system (Fig. 2b). Collectively, these results suggested one or more of the
Trp of apoA1 became the epitope recognized following apoA1 oxidation by the
MPO/H2O2/Cl− system and plays an important role as an “oxidative switch” for impairment
of cholesterol efflux activity.
To further define the oxidized Trp residue that serves as the epitope recognized by mAb
r8B5.2 and its functional significance, we generated additional site-specific mutant apoA1
forms in which each of the four Trp were converted singly to Leu (W8L, W50L, W72L and
W108L) or a subset of sites W72,108 were singly mutated to Phe (W72F and W108F).
Examination of each recombinant mutant apoA1 in native and MPO-oxidized forms
indicated antibody (mAb r8B5.2) recognition was acquired for every apoA1 mutant
following oxidation except for those with site-specific mutation of Trp 72 (Fig. 2a). Parallel
competition experiments using molar excess of different oxidized forms of Trp (as free
amino acids) suggested an oxygen at the 2-position of the indole ring was important for
epitope recognition (Supplementary Fig. 2). Independent confirmation of a 2-oxindolyl
alanine (2-OH-Trp moiety at tryptophan 72 of apoA1) (oxTrp72-apoA1) as the recognition
site for mAb r8B5.2 was achieved by two additional competition ELISA studies: (i) the first
involving synthetic peptides based upon the apoA1 sequences that span each of the 4
different Trp residues of apoA1 in either native form (with Trp), or harboring instead a 2OH-Trp (Fig. 2c); and; (ii) the second involving synthetic peptides in which the apoA1
sequence spanning Trp72 was examined as native form, or as either 2-OH or 5-OH indole
oxidized forms (Fig. 2d).
We next sought to determine the functional significance of Trp72 with respect to cholesterol
acceptor activity within apoA1 in native and MPO-oxidized conditions. Exposure of native
recombinant human apoA1 to increasing levels of oxidation by the MPO/H2O2/Cl− system
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initially, at molar ratios of H2O2:apoA1 of ~ 0–2, results in little loss of ABCA1-dependent
cholesterol efflux activity (Fig. 2e). Proteomics studies reveal formation of methionine
sulfoxide in the three apoA1 Met residues over this interval (data not shown). Upon modest
further additions of oxidant exposure, there is abrupt dose-dependent inhibition in ABCA1dependent cholesterol acceptor activity with virtually no remaining activity at H2O2:apoA1
mol ratio of 10:1 (Fig. 2e), an oxidant exposure within the upper end of that observed within
atherosclerotic plaques based upon protein-bound 3-chlorotyrosine content of the apoA1 as
monitored by LC/MS/MS analyses (Supplementary Fig. 1d). In contrast, the 4WF apoA1
mutant is remarkably resistant to oxidative inactivation of ABCA1-dependent cholesterol
acceptor activity, demonstrating the same activity even in the presence of 50-fold molar
excess of oxidant (relative to apoA1; Fig. 2e), consistent with prior reports28. We next
examined site-specific mutation of just apoA1 Trp 72 into a relatively oxidant resistant
hydrophobic residue (Phe or Ala). An approximate 50% reduction in ABCA1-dependent
cholesterol efflux activity was observed at a 10-fold molar excess of oxidant exposure by the
MPO/H2O2/Cl− system. Alternatively, mutation of the other three Trp residues of apoA1 to
Phe but not Trp 72 (3F72W mutant) showed similar extent (~50%) of functional inactivation
under comparable oxidant exposure (10:1, mol:mol of H2O2:apoA1) (Fig. 2e,
Supplementary Fig. 1d). Collectively, these studies indicate oxidation of Trp72 of apoA1
yielding a 2-oxindolyl alanine (2-OH-Trp) moiety plays a critical role (approximately 50%)
in loss of cholesterol acceptor function of the lipoprotein following exposure to the
MPO/H2O2/halide system (Fig. 2e). They also demonstrate mAb r8B5.2 specifically
recognizes oxTrp72-apoA1 (henceforth we will call apoA1 detected by mAb r8B5.2
“oxTrp72apoA1” to indicate the epitope recognized).
Human aortic plaque apoA1 harbors a 2-OH-Trp72 group and is “dysfunctional”
Utilizing this novel immunological tool, we first sought to show that oxTrp72-apoA1 was
present in human atherosclerotic lesions. Immunohistochemical staining of human
atherosclerotic plaque vs. normal human aorta revealed that oxTrp72-apoA1 is only observed
within atherosclerotic lesions (Fig. 3a). Parallel staining of tissues with antibody to MPO
revealed overall similar staining pattern, though weak MPO staining was also detected along
the endothelial surface, within endothelial cells, and the narrow sub-endothelial space of
normal human aorta (Supplementary Fig. 3a,b). We next used human aortic plaque as a
tissue source for characterization of its oxTrp72-apoA1. An SDS-PAGE analysis of the low
speed supernatant of human aortic plaque homogenate (n=5 subjects) that was examined
before and after buoyant density ultracentrifugation to separate a global lipoprotein fraction
(d ≤ 1.21) from the “lipoprotein-depleted” (LPD) fraction (d > 1.21) is shown in Figure 3b.
Parallel Western blot analyses using anti-oxTrp72-apoA1 (mAb r8B5.2) revealed that
virtually all detectable oxTrp72-apoA1 resided as a lipid-poor soluble form (i.e. nonlipoprotein associated) (Fig. 3c). More detailed quantification showed recovery of ~80% of
the oxTrp72-apoA1 within human aortic plaque homogenate in the LPD fraction, and <1%
within the lipoprotein containing fraction (Fig. 3d).
We next sought to characterize the function of the oxTrp72-apoA1 recovered from human
atherosclerotic plaque. Affinity columns with covalently linked mAb r8B5.2 were used to
immuno-affinity isolate ox-apoA1 harboring the 2-OH-Trp72 moiety from human artery
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lesion homogenate. Examination of the affinity isolated oxTrp72-apoA1 by SDS-PAGE
showed it was pure, with major visible bands at the molecular weight anticipated for the
apoA1 monomer and dimer. Proteomics analyses directly detected the tryptic peptides
containing oxTrp72(OH) (Supplementary Fig. 3c), and virtually no recovered tryptic
peptides harboring native (unoxidized) Trp72 were observed. Further, proteomics studies of
excised bands corresponding to the presumed monomer, dimer, trimer, and higher molecular
weight cross-linked forms of apoA1 revealed all contained predominantly apoA1
(Supplementary Table 1a and 1b). The cholesterol acceptor function of oxTrp72-apoA1
recovered from aortic lesions from multiple subjects (n=6) was next examined. Despite
using over twice the concentration (10 μg ml−1) of oxTrp72-apoA1 recovered from human
atherosclerotic lesions as cholesterol acceptor compared to native human apoA1, only
negligible ABCA1-dependent cholesterol efflux activity was observed (Fig. 3f).
Collectively, these results directly demonstrate that a MPO-modified apoA1 form present
within human atheroma, oxTrp72-apoA1, is predominantly non-HDL (lipoprotein)
associated, and dysfunctional (with respect to cholesterol efflux activity).
OxTrp72-apoA1 is pro-inflammatory and formed during inflammation
In parallel studies we examined the distribution of oxTrp72-apoA1 in the circulation. Plasma
from multiple healthy subjects was fractionated by buoyant density ultracentrifugation, and
the level of oxTrp72-apoA1 determined within each fraction. Notably, similar to human
atherosclerotic plaque, virtually all detectable oxTrp72-apoA1 in plasma was observed to
reside in the LPD fraction (d > 1.21), with only nominal levels recovered in HDL (d =
1.063–1.21) (Fig. 4a–c). Because of the possibility that the high shear forces of
ultracentrifugation might “knock off” oxTrp72-apoA1 from HDL, we performed
independent studies to verify these findings. Plasma was recovered from 10 healthy (> 50 yr
old) subjects with no known CAD and used for immuno-isolation of HDL with polyclonal
antibodies (anti-HDL IgY) raised in chickens against human HDL and covalently attached
to resin. Separate characterization studies of the IgY antibody binding characteristics
revealed preferential recognition of lipidated (HDL-associated) apoA1, but also clear
recognition of lipid-free apoA1 too (data not shown). Coomassie blue staining of native gels
performed using the immune-affinity recovered material from plasma confirmed recovery of
HDL from each subject (Supplementary Fig 4a). Western blot analyses with a mAb that
equally recognizes both native and oxidized forms of apoA1 and HDL similarly confirmed
the presence of apoA1 within the immuno-affinity isolated HDL/apoA1 from each subject
(Supplementary Fig 4b). In contrast, Western blot analyses of native gels with mAb r8B5.2
did not detect any recovered material within the HDL fractions even with extensive overexposure, despite detecting the positive control (Supplementary Fig 4c). If the larger
amounts of the samples were instead examined by SDS-PAGE and Western blot using mAb
r8B5.2 and extensive over-exposure, bands were observed (see below). Together, these
results indicate that oxTrp72-apoA1, while present within the circulation, does not reside to
any major extent on an HDL particle, but rather, is present as a low abundance lipid-poor
apoA1 form in the LPD fraction.
To characterize its biological activity, we next used mAb 8B5.2 to immuno-affinity isolate
oxTrp72-apoA1 from the circulation. As shown in Fig. 4d, Coomassie Blue staining of the
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recovered protein revealed it was quite pure, with the major visible bands corresponding to
the apoA1 monomer and oxidative cross-linked dimer. Proteomics analyses confirmed the
recovered bands as apoA1, with multiple peptides containing oxidized residues noted
(predominantly Trp and Met; Supplementary Table 1c). Parallel Western blot analyses of the
immunopurified apoA1 readily showed bands at the anticipated molecular weight of the
apoA1 monomer and dimer using an mAb that recognizes native and oxidized apoA1 forms
alike (mAb 10G1.5, “anti-total” apoA1)25, as well as with anti-oxTrp72-apoA1 (i.e. mAb
r8B5.2; Supplementary Fig. 4d). Parallel control Western blot analyses showed no
significant light or heavy chain immunoglobulin contamination under the conditions
employed (Supplementary Fig. 4d). We and others have shown that HDL isolated from
healthy volunteers promotes anti-inflammatory effects when incubated with bovine aortic
endothelial cells, whereas apoA1 or HDL modified by MPO ex vivo converts the lipoprotein
into a pro-inflammatory particle29. We therefore examined the pro-inflammatory properties
of oxTrp72-apoA1 recovered from the circulation of apparently healthy middle aged (>50 yr
old) donors (n=12). For comparison, total apoA1 was isolated from the same donors using
polyclonal antibodies raised in chickens (IgY) against native (total) human apoA1 (Fig. 4e).
Notably, when oxTrp72-apoA1 recovered from each subject’s plasma was incubated with
bovine aortic endothelial cells, a marked pro-inflammatory effect was observed as
monitored by substantial increases in surface VCAM1 protein. In contrast, when apoA1
recovered from plasma with IgY immunoprecipitation was used or a comparable amount of
plasma protein was used, no pro-inflammatory response in the endothelial cells was noted
(Fig. 4e). Parallel studies confirmed the ability of immuno-isolated lipid-free (organic
solvent extracted) oxTrp72-apoA1 recovered from plasma to promote endothelial cell NF-κB
activation and nuclear localization, similar to in vitro oxidized lipid-free apoA1 (by MPOH2O2-Cl− system) and IL-1 exposure as positive controls. The pro-inflammatory behavior
observed with lipid-free oxTrp72-apoA1 contrasts with the lack of NF-κB activation
observed using lipid-free apoA1 isolated from plasma HDL recovered during either buoyant
density ultracentrifugation or an affinity column generated with anti-human apoA1 IgY and
employed under conditions that quantitatively removed apoA1 from plasma (Fig. 4f).
We next investigated whether formation of oxTrp72-apoA1 is specific to atherosclerotic
plaque only or if it is formed in other sub-acute inflammatory conditions, such as peritonitis
(induced by i.p. injection of yeast cell wall protein carbohydrate components, zymosan). We
have previously shown MPO serves as a major enzymatic catalyst for both protein and lipid
oxidation within the model35. Formation of oxTrp72-apoA1 was readily detected over time
in both peritoneal lavage fluid (not shown) and plasma in human apoA1-Tg mice,
demonstrating endogenous human apoA1 may be targeted for post translational modification
at Trp72 during sub-acute inflammation (Fig. 4g). Thus, apoA1 may be oxidized at a local
site of inflammation, whether it be the artery wall or an inflamed peritoneal cavity, and then
diffuse into the circulation.
OxTrp72-apoA1 has impaired ABCA1-dependent HDL biogenesis activity in vivo
ABCA1 is critical for HDL biogenesis and hepatocyte ABCA1 expression accounts for
nearly 80% of plasma HDL production36. Given that MPO potently inhibits ABCA1dependent cholesterol efflux activity of apoA1/HDL in vitro, and our site-directed

201

mutagenesis studies support a critical role for apoA1 Trp72 in ABCA1-dependent efflux
activity (Fig. 2e), we wanted to demonstrate that oxTrp72-apoA1 recovered from human
plasma has impaired capacity to stimulate HDL biogenesis in vivo. We first focused our
attention on development of an animal model in which to monitor nascent HDL particle
formation in vivo via an ABCA1-dependent pathway. Injection of lipid-free human apoA1
sub cutaneously (s.c). into apoA1-KO mice was shown to result in appearance of apoA1 into
the vascular compartment (i.e. plasma), incremental increases in circulating HDL particle
cholesterol content, and incorporation of human apoA1 into the HDL particle pool (Figs.
5a–d). To determine if these were ABCA1-dependent phenomenon, we performed parallel
studies injecting lipid-free human apoA1 s.c. into hepatocyte-specific ABCA1-KO mice vs.
the appropriate WT controls36. The time-dependent increases in HDLc observed in plasma
following apoA1 injection demonstrated an absolute requirement for ABCA1, and the
majority of human apoA1 appearance within the HDL fraction was attenuated in the
hepatocyte-specific ABCA1-KO mouse (Supplementary Figs. 5a–c).
Using this in vivo model of “ABCA1-dependent HDL biogenesis”, we next examined
whether oxTrp72-apoA1 recovered from human plasma was indeed dysfunctional in vivo.
Injection of apoA1-KO mice s.c. with equivalent amounts of either lipid-free native human
apoA1 or immunoaffinity isolated oxTrp72-apoA1 resulted in comparable time-dependent
appearance of total apoA1 in the circulation (Fig. 5a). However, whereas native human
apoA1 s.c. injection induced incremental increases in HDLc levels over a short period of
time (2h), injection of the oxTrp72-apoA1 did not increase HDLc levels (despite being in the
vascular compartment), and even reproducibly slightly reduced HDLc levels (Fig. 5b).
Native human apoA1 appearing in the circulation resided entirely within HDL particles (Fig.
5c), whereas oxTrp72-apoA1 remained predominantly within the LPDF (Fig. 5d). Of note,
while lipid-free apoA1 modified by the MPO/H2O2/Cl− system in vitro is capable of
forming a reconstituted nascent HDL particle using the cholate dialysis method (data not
shown), it similarly (to oxTrp72-apoA1 recovered from human plasma) fails to interact
productively with ABCA1 facilitating cholesterol efflux and nascent HDL formation (Fig.
2b,2e).
We next tested whether an apoA1 form in which Trp72 is mutated to Phe (72WFapoA1),
which is more resistant to MPO-catalyzed oxidative inactivation in vitro (Fig 2e),
demonstrated improved biological function relative to native human apoA1 following
oxidation. Native “wild type” recombinant human apoA1 (rh-apoA1) and 72WFapoA1 were
each examined for in vivo HDL biogenesis activity in native and MPO-oxidized form.
Within 2h of s.c. injection of native rh-apoA1 into apoA1-KO mice, incremental increases in
HDLc were observed within plasma, consistent with de novo HDL biogenesis (Fig. 5e). In
contrast, s.c. injection of rh-apoA1 exposed to the MPO-H2O2-Cl− system (apoA1:H2O2,
10:1) was accompanied by time (within 2h) dependent decrease in HDLc level (Fig. 5e).
Parallel studies using the 72WFapoA1 mutant revealed comparable levels of total apoA1
within the vascular compartment following s.c. injection of either native or oxidized forms
of rh-apoA1 and 72WFapoA1 (Supplementary Fig. 6a). Further, similar magnitude increase
in HDLc was observed following s.c. injection of the unmodified mutant apoA1, and no
reduction in HDLc levels following s.c. injection of ox72WFapoA1 (Fig. 5e). Examination
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of the HDL particle distribution of the injected apoA1 forms revealed more significant
differences (Fig. 5f, Supplementary Fig. 6b). Whereas MPO-catalyzed oxidation of rhapoA1 produced an oxapoA1 form that in majority failed to become incorporated into an
HDL particle, mutation of apoA1 Trp72 to Phe completely protected the mutant apoA1
form, permitting virtually all circulating ox72WFapoA1 to become incorporated into HDL
particles (Fig. 5f). Thus, site-specific mutation of apoA1 at Trp 72 into the more oxidant
resistant residue Phe produced a mutant apoA1 form with some protection from oxidative
loss in HDL biogenesis activity, consistent with in vitro data demonstrating improved
interaction with ABCA1 following exposure to MPO-catalyzed oxidation (Fig. 2e).
OxTrp72-apoA1 is abundant in human atheroma and plasma levels predict CVD risk
To quantify the content of oxTrp72-apoA1 in human plasma and aortic atherosclerotic
plaque homogenate we developed a sandwich immunoassay using mAb r8B5.2 as the
capture antibody, and as detecting antibody we used a mAb previously developed that
recognizes native vs. oxidized and lipid-free vs. HDL-associated apoA1 forms to a
comparable extent (anti-total apoA1, mAb 10G11.5;25). Sequential consenting subjects (n =
627) undergoing elective risk factor evaluation and cardiac examination in an outpatient
preventive cardiology clinic were examined. Supplementary Table 2a shows the clinical and
demographic characteristics of the cohort, of which 35% had clinical evidence of CVD.
Quantification of oxTrp72-apoA1 and total apoA1 levels in plasma of the entire cohort
revealed that on average only 0.007% of the apoA1 in plasma harbors the 2-OH-Trp72
moiety, and that there was wide variation in levels among the subjects (Fig. 5g). In contrast,
oxTrp72-apoA1 represented 20% of total apoA1 within atherosclerotic plaque-laden aorta (n
= 10), over 1000-fold more abundant (relative to total apoA1) than observed in plasma (Fig.
5g; Supplementary Fig. 7a,b). For further illustrative purposes, plasma from a random
sampling of non-CVD (n=8) and CVD subjects (n=8) are shown following SDS PAGE and
either Coomasie Blue staining for protein, or Western blot analyses using each mAb
employed in the sandwich immunoassay (Supplementary Fig. 7c–e). Examinations of the
distribution of HDLc and apoA1 levels within the entire cohort reveal the expected inverse
correlations with CAD and CVD in the cohort (Supplementary Fig. 7f–i). In contrast, the
distribution of both the absolute concentration of oxTrp72-apoA1 and the ratio of oxTrp72apoA1/total apoA1 within the entire cohort showed significantly higher levels in subjects
with either CAD or CVD compared to their corresponding controls (i.e. non-CAD or nonCVD; Fig. 5h). Further analyses of circulating oxTrp72-apoA1 levels (both absolute
concentration and as ratio relative to total apoA1) within the entire cohort revealed that
higher levels, particularly within the 4th quartile relative to 1st, were independently
associated with increased CAD and CVD risks (Fig. 5i, Supplementary Table 2b). The
positive association with increased CAD and CVD risks remained significant even following
adjustments for traditional CVD risk factors, apoA1, MPO and high sensitivity C-reactive
protein levels, and lipid lowering medication use (Fig. 5i, Supplementary Table 2b). The
improvement in model performance introduced by the inclusion of oxTrp72-apoA1 was
evaluated using net reclassification index (NRI) and integrated discrimination improvement
(IDI). AUC was calculated using the area under ROC curve. Though there is no significant
gain in AUC, inclusion of oxTrp72-apoA1 to the fully adjusted model resulted in a
significant improvement in risk estimation, based on NRI (CAD: 4.1%, P < 0.001 CVD:
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5.9%, P < 0.001) and IDI (20% for both CAD and CVD, P < 0.001). Of note, when the
prognostic value of HDLc and apoA1 were similarly examined within the cohort, each
demonstrated the expected inverse association with CVD and CAD risks (Fig. 5i,
Supplementary Table 2b). Comparisons of the odds ratio (95% confidence interval) for
oxTrp72-apoA1 versus traditional risk factors for CVD are shown in Supplementary Table
2c, and illustrate oxTrp72-apoA1 levels are comparable in magnitude to numerous
established risk factors within the cohort.

DISCUSSION
The atheroprotective role of HDL has been questioned due to recent failures of multiple
HDLc raising drugs and mendelian randomization studies showing genetic variants that
control HDLc levels are not associated with risk of CAD16–18,37. Yet there is overwhelming
preclinical data showing apoA1 promotes anti-atherosclerotic functions1,3,5–6. This apparent
contradiction has spurred interest in better understanding the role of the HDL particle in
human coronary artery disease. Ideally, a means of monitoring HDL function in the
circulation should reflect what is occurring within the diseased artery wall. Studies thus far
of apoA1 recovered from human atheroma reveal it is highly oxidized, cross-linked,
dysfunctional (with respect to cholesterol efflux and LCAT activities), and lipid-poor since
it is not associated with an HDL particle25. Despite the recognition that apoA1 in lesions is
heavily oxidized, direct functional interrogation of a structurally specific oxidative
modification on apoA1 recovered from the artery wall has not yet been reported. The present
studies identify for the first time the structural basis of an abundant dysfunctional form of
apoA1/HDL within the artery wall – MPO-catalyzed site-specific oxidation of Trp72 of
apoA1 forming an oxindolyl alanine (2-OH-Trp) moiety. Quantification in human atheroma
reveals it is highly prevalent, accounting for one in five apoA1 within the lesion.
Remarkably, the oxidized apoA1 form, oxTrp72-apoA1, was only nominally HDL particle
associated, with virtually all found in both the artery wall and within plasma as a lipid-poor
form. Thus, studies of HDL-like particles recovered from human arterial lesion homogenates
using buoyant density ultracentrifugation, an approach typically used by some studying
apoA1 from lesions38–39, would essentially miss the vast majority of this abundant modified
apoA1 form in vivo. Of note, lipid-poor apoA1 modified by the MPO/H2O2/Cl- system
acquires pro-inflammatory activities, and lipid-free oxTrp72-apoA1 recovered from human
plasma was capable of activating endothelial cell NF-κB. Whether differences in lipid
binding capability of oxidized vs. native apoA1 forms contribute to pathophysiological
functions is unclear.
An overall scheme of our findings is illustrated in Fig. 6a. Circulating HDL readily diffuses
into the artery wall. Within atherosclerotic lesions, MPO is enriched and promotes sitespecific oxidative modification of apoA1 at residue Trp72. Site-directed mutagenesis studies
show that this residue is essential for ABCA1-dependent cholesterol efflux activity of
apoA1 in vitro, and in vivo animal model studies with the 72WFapoA1 mutant demonstrate
the importance of this residue in loss of apoA1 association with HDL particles in vivo
following MPO-catalyzed oxidation. Recovery of apoA1 from lesions using mAb specific
for recognition of oxTrp72-apoA1 revealed virtually no detectable ABCA1-dependent
cholesterol acceptor activity of the recovered ox-apoA1. Further biological characterization
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of the modified lipoprotein revealed it was lipid-poor, not associated with the HDL particle,
harbored potent pro-inflammatory activity including promotion of endothelial cell NF-κB
activation, nuclear localization and surface expression of VCAM-1 protein, an adhesion
protein with known pro-atherogenic function40. Importantly, direct injection of apoA1
harboring the 2-OH-Trp moiety into apoA1-KO mice confirmed this post-translationally
modified apoA1 form possesses impaired HDL biogenesis activity since it both failed to
elicit any incremental increases in circulating HDLc levels or appear on HDL particles,
despite being at comparable level as native apoA1 within the plasma compartment in the
HDL biogenesis model.
Another intriguing finding is the specificity observed for the MPO/H2O2/Cl− oxidative
system in generating a 2-oxindolyl alanine (2-OH-Trp) moiety on apoA1 at Trp72. Detailed
structural analyses reveals a remarkable specificity for oxidation on the indole ring at the 2
position, as well as at residue Trp72 of apoA1. Examination of the mechanism accounting
for the selective targeting of the Trp72 site of apoA1 by the MPO system and not alternative
oxidation systems appears to have, in part, a structural basis – the close proximity between
the MPO binding site on the anti-parallel apoA1 chain and Trp72 of apoA1 (Fig. 6b). It is
widely believed that apoA1 is configured as anti-parallel amphipathic helices within HDL,
either between two anti-parallel chains, or in some regions, as a hairpin27,41–45. We recently
used small angle neutron scattering with contrast variation to directly visualize the protein
shape of apoA1 within spherical HDL, the most abundant form of HDL in the circulation44.
Coupled with cross-linking mass spectrometry studies and molecular modeling, we
developed a model of apoA1 within spherical HDL44. When the location of apoA1 residues
involved in MPO binding as determined by hydrogen/deuterium exchange (residues A190–
L203)26 are highlighted on this model along with apoA1 Trp72, the distance between Trp72
and the MPO binding region on each of the apoA1 chains is remarkably short, ranging
between a maximum predicted length of 18 Å to a minimal distance of only 6 Å (Fig. 6b).
The predicted distance between Trp72 of one apoA1 chain and the MPO binding site in
nascent HDL similarly shows a short diffusion distance (14Å) (Supplementary Fig. 8). The
oxidant formed by the MPO/H2O2/Cl- system, HOCl, is highly reactive, and is rapidly
scavenged by the first susceptible target it encounters (which is virtually any amino acid,
though Met, Cys, His, Trp, Lys and Tyr are most reactive46). The short diffusion distance
between the MPO binding site and Trp72 of all HDL models examined no doubt contributes
to the remarkable selective targeting of Trp72 for oxidative modification by MPO (Fig. 6b).
While quantification of oxTrp72-apoA1 reveals it to be highly enriched within the
atherosclerotic plaque, no detectable immunostaining with mAb 8B5.2 was observed within
normal aortic tissue. Thus, within the artery wall, MPO-dependent oxidative modification of
apoA1 appears to be highly correlated with the atherosclerotic disease process. However,
our studies also observed increases in circulating oxTrp72-apoA1 levels in human apoA1-Tg
mice during a sub-acute inflammation model. Thus, apoA1 may be oxidized at a local site of
inflammation, whether it be the artery wall or an inflamed peritoneal cavity, and then diffuse
into the circulation. Based upon its mechanism of formation, one would not anticipate that
detection of oxTrp72-apoA1 in the circulation would serve as a specific indicator of
atherosclerosis. None-the-less, multilogistic regression analyses within the clinical cohort
examined demonstrates that elevated levels of the dysfunctional apoA1 form are sufficiently
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selectively associated with CAD and CVD risks so as to remain statistically significant
following adjustments for multiple traditional risk factors including apoA1, MPO and other
markers of inflammation. It is tempting to speculate that the pro-inflammatory biological
activity observed with oxTrp72-apoA1 may render it pro-atherogenic, thus possibly serving
as a contributor to the well-recognized phenomenon of increased CVD risk during chronic
inflammatory conditions. However, further studies are needed to test this intriguing
hypothesis.
Given the 1000-fold enrichment of oxTrp72-apoA1 content (relative to total apoA1) in
atheroma and our histological studies, our studies suggest that formation of the modified
apoA1 form occurs within the protected environment of the subendothelial space (Fig. 6a),
and the oxTrp72-apoA1 observed within the circulation reaches the intravascular
compartment by diffusion out of the artery wall. MPO has been shown to accumulate within
the subendothelial compartment47, and it has been mechanistically linked to formation of
vulnerable plaque, such as through catalytic consumption of nitric oxide48–49, activation of
matrix metalloproteinase pathways50, or promotion of endothelial cell apoptosis and
superficial erosions within culprit lesions51. Indeed, it is of interest that MPO is being
examined as a potential target for functional imaging of vulnerable plaque52–53. The present
studies suggest that quantification of oxTrp72-apoA1 within the circulation may serve as a
gauge of molecular processes that impair apoA1/HDL function in the artery wall, and thus
serve as a new diagnostic and therapeutic target in CAD.

Online methods
Materials
Human MPO was isolated and characterized as described54. [3H]Cholesterol was obtained
from Amersham Biosciences (Pisc-ataway, NJ). L-[13C6]tyrosine, L-[13C9,15N1]tyrosine,
[13C6,15N1] Leucine, L-[13C9,15N1]Phenylalanine, and L-[13C5,15N1]Valine were purchased
from Cambridge Isotope Laboratories Inc. (Andover, MA). Mouse immunoglobulin
isotyping kit was obtained from GIBCO BRL (Life Technologies GmbH). Trypsin was from
Promega (Madison, WI) and all cell lines were from the American Type Culture Collection
(Rockville, MD). 5-hydroxy-L-tryptophan was purchased from MP Biomedicals (Solon,
OH). 6-Hydroxyindole and 7-hydroxyindole were purchased from Chem-Impex
International Inc. (Wood Dale, IL). All peptides were synthesized by the CS Bio Company,
Inc. (Menlo Park, CA). All other reagents were obtained from Sigma-Aldrich (St. Louis,
MO) unless otherwise specified.
General procedures
All study protocols were approved by the Institutional Review Board of the Cleveland
Clinic, and all subjects gave written informed consent. All mouse studies were performed
under protocols approved by the Institutional Animal Care and Use Committee at the
Cleveland Clinic.
Circulating HDL and plasma-derived purified apoA1 were obtained from healthy volunteer
donors as previously described55. Protein content was determined by the Markwell-modified
Lowry protein assay56 with BSA as standard. Recombinant human apoA1 was generated in
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an Escherichia coli expression system and isolated by sequential column chromatographies
as described26,57. Briefly, rh-apoA1 and mutants were expressed in Escherichia Coli strain
BL21 (DE-3) pLysS. All the mutations were made by using the QuickChange Mutagenesis
Kit (Stratagene, La Jolla, CA) and confirmed by DNA sequencing. 4WF and 4WL represent
recombinant human apoA1 in which all of the endogenous tryptophans (residues 8, 50, 72,
and 108) were converted to phenylalanine or leucine, respectively. W8L, W50L, W72L,
W72F, W108F and W108L are recombinant human apoA1 mutants with the indicated single
tryptophan mutation. 3MV is an apoA1 mutant in which all three methiones (at residues 86,
112, and 148) were mutated to valine. 7YF is an apoA1 mutant in which all seven tyrosines
(at residues 18, 29, 100, 115, 166, 192, and 236) were converted to phenylalanine.
Reconstituted nascent HDL was prepared using the modified sodium cholate dialysis
method58 at an initial molar ratio of 100:10:1 of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholine):cholesterol:apoA1. To totally remove all endotoxin from purified
recombinant apoA1, all mutants were lipidated (using POPC:apoA1, 100:1 mol:mol)
forming nascent HDL, and then delipidated by organic solvent extraction for 6 consecutive
rounds. Endotoxin levels in all recombinant apoA1 were confirmed to be nominal (< 0.5
EU/mg/ml protein) by Limulus amoebocyte lysate assay (Charles River Laboratories,
Wilmington, MA). Concentrations of apoA1 mutants were determined by both their
predicted extinction coefficient at 280nm and amino acid composition analyses following
HCl hydrolysis (in pure form). Accuracy of protein concentrations of isolated pure apoA1
mutants was determined by stable isotope dilution LC/MS/MS analyses on an AB SCIEX
5000 triple quadrupole mass spectrometer using synthetic L-[13C9,15N1]tyrosine,
[13C6,15N1]leucine, L-[13C9,15N1]phenylalanine, and L-[13C5,15N1]valine as internal
standards, and predicted sequence of the mutant. The concentration of H2O2 was determined
spectrophotometrically (ε240 = 39.4 M−1cm−1). HOCl was added as NaOCl into buffered
reaction mixtures. The concentration of NaOCl was determined spectrophotometrically
(ε292=350 M−1cm−1). Peroxynitrite(ONOO−) was quantified spectrophotometrically (ε302=
1670 M−1cm−1). Protein-bound ClTyr was quantified by stable isotope dilution LC/MS/MS
analyses using synthetic 3-Cl[13C6] tyrosine and L-[13C9,15N1] tyrosine as internal standards
on an AB SCIEX 5000 triple quadrupole mass spectrometer as described26,35. Monoclonal
antibodies specific for apoA1 or MPO modified apoA1 (exposed to MPO/H2O2/Cl− or
MPO/H2O2/NO2− system; H2O2:apoA1 molar ratio of 5:1) were generated via hybridoma
technology59. Cholesterol efflux (ABCA1-dependent and total) activity of apoA1 was
determined as described26. Specifically, RAW264.7 cells (ATCC,Rockville, MD) were
treated with 2 μg ml−1 of apoA1 (Fig. 2b,e) or indicated amount of proteins in (Fig. 3f) for 6
hours. Efflux to cholesterol acceptor was calculated as described26. 2,3,-Dioxindolyl alanine
and 2-oxindoly lalanine were synthesized as described in a prior publication60. Western blot
quantification was done using either ImageJ software (version 1.46, http://rsbweb.nih.gov/ij/
index.html) or Image Studio software (version 2, LI-COR Biosciences, Lincoln, NB). HDL
containing lipoprotein fraction (d ≤ 1.21 g ml−1) and LPD fractions (d > 1.21 g ml−1) were
recovered from plasma or tissue homogenate by sequential buoyant density
ultracentrifugation using sucrose and D2O to avoid high ionic strength associated alterations
to protein compositions of lipoprotein particles observed with KBr use61. Mice plasma (10–
40μl) was diluted to 500μl with 1XPBS buffer (pH 7.0) and 887 μl of sucrose D2O buffer(d
=1.325 g ml−1; 0.1742 g K2HPO4, 0.1361 g KH2PO4, 0.8182 g NaCl, 111.1 g sucrose and
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100 ml of D2O). The fraction with density less than 1.21 g ml was obtained after a 48 h
ultracentrifugation at 40,000 rpm at 20°C (Beckman rotor 50.4Ti, 8×49mm ultra-clear
centrifuge tubes). The lipoprotein fraction (d ≤ 1.21 g ml−1) was recovered by slicing the
upper 0.25 ml of the tube. HDL cholesterol precipitating reagent (StanBIO Laboratory, Cat.
No. 0599) was added into mice plasma to precipitate LDL, and HDL cholesterol was
quantified by stable isotope dilution gas chromatography mass spectrometry analyses62.
Phage display and affinity maturation of parental antibody
A single chain (scFv) phage display library was constructed by using the cDNA derived
from the 8B5.2 hybridoma cell line using methods as described by Barbas et al63. The
murine Kappa variable light chain families VK1 to VK17 and the variable heavy chain
families VH1 to VH19 were amplified using 26 pairs of family-specific primers and then the
variable light chain and variable heavy chain sequences “stitched” together via a flexible
linker (SSGGGGSGGGGGGSSRSS) using overlap PCR and cloned into phagemid
pCOMB3 as described63. Recombinant phages were prepared from the library with the
helper phage M13K07 at a multiplicity of infection of ~10. The library was selected using
immunotubes (Costar #3690) coated with 0.5 ml 25 μg ml−1 Cl.apoA1 (apoA1 exposed to
the MPO/H2O2/Cl− system at 10:1 molar ratio of H2O2 to apoA1) in 50 mM carbonate
buffer, pH 9.6 overnight at 4°C64 The rescue-selection-plating cycle was repeated three
times. For affinity maturation, another phage display scFv library was constructed by errorprone PCR and followed by passaging the library in XL1-red mutator E. coli (Stratagene,
LaJolla, CA) for four times. Screening of scFv by dissociation rate constant (Koff) was
performed using real-time biospecific interaction analysis based on surface plasmon
resonance (SPR) in a Biacore 2000 (GE Healthcare Life Sciences, Piscataway, NJ). A third
library was generated by introducing all combinations of mutant residues found in the nine
individual clones into variable regions of the scFv gene. The scFv gene was subcloned to a
dicistronic baculoviral shuttle vector (a generous gift from Mifang Liang, China CDC) then
recloned into a mammalian expression vector and the dicistronic alleles expressed in DG44
CHO cells as a chimeric human IgG antibody.
Surface plasmon resonance—In a Biacore flow cell, approximately 2,000 resonance
units (RU) of Cl.apoA1 (5 μg ml−1) in 10 mM sodium acetate, pH 4.5 was coupled to a CM5
sensor chip. Association and dissociation rates of original 8B5.2 and recombinant affinity
matured antibody were measured under continuous flow of 30 ml min−1 using a
concentration range from 0.7 to 1000 nM. The Ka1 and Kd1 values were calculated using
BIAeveluation software and sensorgrams were fitted by a bivalent model. The apparent KD
was calculated from the ratio of Kd1/Ka1.
Immunopurification of oxTrp72apoA1—Antibodies were covalently coupled to
UltraLink Hydrazide Resin (Pierce Chemical Co., Rockford, IL) for immunoaffinity
isolations of native or oxidized apoA1 forms from plasma. Before immune-affinity
isolations of apoA1 forms, human albumin was first depleted from plasma as follows.
Human plasma was dialyzed in a binding buffer (20 mM MOPS, pH7.0, 100 mM NaCl) and
diluted 4-fold in the binding buffer before it was loaded onto 500 ml column bed of Q
Sepharose XL resin (GE Healthcare Life Sciences, Piscataway, NJ). Albumin depleted
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plasma was collected as flow through (and Western analyses with various anti-apoA1 mAb
confirmed complete recovery of all apoA1 forms as well). This flow through fraction was
delipidated, and to more completely remove contaminating immunoglobulins during the
immune-affinity isolation step, reduced and denatured with guanidine hydrochloride (3 M
final, pH7.8) and dithiothreitol (1mM final). After the denatured fraction was incubated for
1 h at room temperature, the protein was alkylated by the addition of iodoacetamide (2.5
mM final) and incubated for 1 h at room temperature in a foil wrapped container. The
denatured and alkylated fraction was dialyzed against 20 mM Tris.Cl, 150 mM NaCl and
oxTrp72-apoA1 was purified from this solution using a covalently coupled r8B5.2 affinity
column. Total apoA1 was similarly purified using a covalently coupled chicken polyclonal
IgY that recognizes total apoA1 (Genway Biotech, San Diego, CA).
Cell Surface VCAM-1 protein expression—Cell surface VCAM-1 protein levels were
determined in BAEC. The BAEC cells were starved in DMEM for 4 h and then incubated
with 80 μg of protein per ml of HDL, or 80 μg of protein per ml of HDL exposed to
MPO/H2O2/Cl− system (Cl.HDL) or, where indicated, individual protein and plasma for 16
h. After one wash with phosphate-buffered saline, the cells were fixed in 4%
paraformaldehyde for 20 min and blocked in 0.5% casein in PBS with 0.02% NaN3 for 4 h.
Surface VCAM-1 protein was determined using goat polyclonal anti-VCAM-1 primary
antibody (1:4000, catalog # sc-1504, Santa Cruz Biotechnology, Santa Cruz, CA,) with antigoat IgG antibody conjugated with horseradish peroxidase (1:5000, #sc-2020, Santa Cruz
Biotechnology, Santa Cruz, CA,) as a secondary antibody, detection by SureBlue
tetramethylbenzidine peroxidase substrate (KPL Inc., Gaithersburg, MD) and measuring
absorbance at 450 nm on a 96-well plate reader (Spectramax 384 Plus; Molecular Devices,
Sunnyvale, CA) after the addition of 1 M HCl to stop the reaction.
Confocal immunofluorescent analysis—BAEC cells (2 × 104 cells per well) were
inoculated into Lab-Tek Chamber 16 well glass slides (Electron Microscopy Sciences,
Hatfield, PA) for 16 h. The cells were treated with drugs (Fig. 4 panel f) 80 μg ml−1 each at
37°C for 20 mins. The cells were then washed with PBS and fixed with 4%
paraformaldehyde in PBS (15 min, room temperature) and permeabilized by immersion in
0.5% Triton-X100 (10 min, room temperature). Cells were quenched with 100mM glycine
(10 min, room temperature) and blocked in 1%BSA / 10% normal goat serum in PBS, pH
7.0 (1 h at room temperature). Blocked cells were incubated sequentially with primary
antibody NF-κB p65 (E498) (cat # 3987, Cell Signaling Technology, Danvers, MA) diluted
in blocking buffer (overnight, 4 °C) and secondary antibody goat anti rabbit IgG-FITC (cat #
ab6717-1, Abcam, Cambridge, MA) diluted in blocking buffer (100:1, 1 h, room
temperature). Coverslips were mounted on to glass slides using Vectashield DAPI mounting
media (Vector Laboratories Inc., Burlingame, CA). Images were viewed on a Leica
DMRXE confocal microscope (Leica Microsystems Inc. Buffalo Grove, IL) using a 63 X
oil-immersion objective with a 1.40 numeric aperture. Confocal images were acquired using
the Leica Confocal Software Version 2.61.
Immunochemistry staining of atherosclerotic plaques—Fresh human aortic tissue
was obtained as discarded surgical material, both at time of organ harvest from transplant
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donors, and during valve/aortic arch (“elephant trunk”) replacement surgery.
Immunohistochemistry of atherosclerotic plaque and normal aorta was carried out on fresh
frozen sections. The anti-oxTrp72apoA1 antibody (r8B5.2 Fab) version and polyclonal rabbit
anti human MPO (#A0398, Dako North America, Inc., Carpinteria, CA) were used at a
dilution of 1:400. Mouse normal IgG1 (X0931, Dako North America, Inc., Carpinteria, CA)
was used as control for antibody staining. The staining procedure followed the protocol of
the DakoCytomation Envision+ system HRP(AEC) (Dako North America, Inc., Carpinteria,
CA).
Aortic tissue homogenization—At time of harvest, all tissues were immediately rinsed
in ice-cold PBS supplemented with 100 μM diethylenetriamine pentaacetic acid (DTPA) and
frozen at −80°C in argon-sparged buffer A (65 mM sodium phosphate, pH 7.4, 100 μM
DTPA, 100 μM butylated hydroxytoluene) in gas tight containers overlaid with argon, which
were kept within larger argon flushed sealed containers. At time of use, samples sealed in
gas-tight containers were placed in ice/water bath. Immediately before complete thaw, the
tissues were rinsed five times with ice-cold argon sparged Ca2+ and Mg2+-free PBS
supplemented with 100 μM DTPA to remove any residual visible hemaglobin. The aorta
segment was rapidly cleaned of fatty tissues and placed in a Petri dish containing ice-cold
PBS buffer. The adventitial layer and outer portion of the media were carefully peeled from
the vessel to give a clean “smooth” aorta. The aorta was rinsed with ice-cold PBS three
times and the wet weight of the aorta was determined. The tissue was then cut into small
pieces (about 3 to 5 mm in diameter) in a Petri dish cover on ice. Tissue pieces were
suspended in ice-cold Ca2+ and Mg2+-free PBS containing a protease inhibitor cocktail. The
protease cocktail PMSF (1 mM) and Sigma-Aldrich protease inhibitor cocktail (catalog no.
P8340) were included in all subsequent solutions used for lipoprotein isolation. Aortic tissue
was homogenized on ice with a Polytron Tissue Homogenizer (Model PT 10/35, Brinkman
Instruments Inc., Westbury, NY) for 1 min followed by 5 × 30 sec intervals in ice/water
bath. The homogenate was then centrifuged at 12,000 × g for 30 min. The pellet was
discarded and the supernatant stored on ice until use. HDL and LPD fractions were
separated by ultracentrifugation using a sucrose and D2O protocol61.
Indirect ELISA—Nunc MaxSorp ELISA plates (#446612, Thermo Fisher Scientific,
Waltham, MA) were coated with the indicated purified native or oxidized protein (0.2 μg
ml−1) in Carbonate and Bicarbonate buffer, pH 9.6. Purified human apoA1, rh-apoA1 and
mutant apoA1’s were modified by either the MPO/H2O2/Cl− system, the MPO/H2O2/NO2−
system or by multiple other oxidation systems as indicated at 10:1 molar ratio of oxidants/
apoA1, unless otherwise specified, details of oxidation conditions are described in reference
25. Primary antibody r8B5.2 (50 ng ml−1) (Fig. 1d and Fig. 2a,e) was added into the 5%
BSA blocked ELISA wells and incubated for 1 hr at room temperature. The plates were then
washed with PBS, 0.05% Tween 20 (PBST) 4 times. The signal was detected by Peroxidase
AffiniPure Goat Anti-Mouse IgG, F(ab’)2 Fragment Specific (1:10,000 dilution, Code #
115-036-006, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA)
Competitive ELISA—Nunc MaxSorp ELISA plates (#446612, Thermo Fisher Scientific,
Waltham, MA) were coated with 0.5 μg ml−1 Cl.apoA1 in Carbonate and Biocarbonate
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buffer, pH 9.6. (human apoA1 modified by MPO/H2O2/Cl− complete oxidative system at
10:1 molar ratio of H2O2/apoA1). r8B5.2 (25 ng ml−1) and peptides were added into the 5%
BSA blocked ELISA wells and incubated for 1 hr at room temperature. The signal was
detected by Peroxidase AffiniPure Goat Anti-Mouse IgG, F(ab’)2 Fragment Specific
(1:10,000 dilution, Code # 115-036-006, Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA).
Sandwich ELISA—Costar ELISA plates (#3690) were coated with capture antibody
r8B5.2 (50 μl per well, 7 μg ml−1 in 0.1M Tris.Cl pH8.5) at 4°C for overnight. Except for
the capture antibody coating process, all other reactions were performed at room
temperature (20 °C). Coated plates were washed with PBS buffer twice, and then washed
plates were blocked with 170 μl of blocking buffer [1% fish peptone (Fluka Biochemika,
CAT# 93490), 3% BSA (Sigma cat# A7030), 2% Poly Vinyl Alcohol, 0.05% Tween 20 in
PBS, pH 7.4] for 2 h. A calibration curve was constructed with Cl.apoA1 (8 pM – 8nM) in
sample dilution buffer (1% salmon serum, 0.05% Tween 20 in PBS, pH 7.4). Pooled plasma
samples which had been aliquoted into single use samples were thawed once and used as
controls on every plate. Plasma samples were diluted in sample dilution buffer (1% salmon
serum, 0.05% Tween 20 in PBS, pH 7.4). Diluted samples were added into the blocked EIA
wells at 50μl per well and incubated for 45 min. The plates were then washed with PBST 4
times. Detecting mAb 10G1.5 (anti-total apoA125) was diluted (1:40,000) in antibody
dilution buffer (0.03%BSA (Sigma cat# A7030) in PBST) and incubated in EIA well at 50
μl per well for 30 min. After four washes with PBST, HRP conjugated neutravidin (Cat
#31001, Pierce Chemical Co. Rockford, IL; 1:10,000 diluted in antibody dilution buffer,)
was added into the ELISA plates (50 μl per well) and incubated for 30 min. The ELISA was
developed with SureBlue TMB substrate (Cat. #52-00-0, KPL, Inc., Gaithersburg, MD) and
read at O.D. 450nm.
Research subjects—Levels of oxTrp72-apoA1 were determined in sequential consenting
subjects presenting to the Preventive Cardiology outpatient clinic of the Cleveland Clinic as
part of an observational study called BioBank. Fasting plasma samples and associated
clinical data were collected at time of patient visit. CAD definition included adjudicated
diagnoses of stable or unstable angina, myocardial infarction, angiographic evidence of >
50% stenosis of one or more major epicardial vessels or history of coronary
revascularization. PAD was defined as any evidence of extra-coronary atherosclerosis or
ABI <0.9. Atherosclerotic CVD was defined as the presence of either CAD or PAD. Patients
who had experienced a myocardial infarction or stroke within 1 month preceding enrollment
were ineligible. All subjects gave written informed consent and the Institutional Review
Board of the Cleveland Clinic approved all study protocols.
Mice models—Breeders of all conventional mice (C57BL/6J, apoA1 Tg+/+ and apoA1−/−
mice on a C57BL/6J background) were obtained from Jackson Laboratories. Wildtype fl/fl
(WT fl/fl) and hepatocyte-specific ABCA1 knockout apoA1 (ABCA1 KO) mice on a
C57BL/6J background have been described36,65. All animal studies were performed under
approval of the Animal Research Committee of the Cleveland Clinic. To induce a subacute
peritonitis model, apoA1 Tg+/+ animals were injected i.p. with zymosan. Plasma was
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obtained at baseline before injection, and then serially (1, 2 and 3 days) following injection.
OxTrp72-apoA1 levels in plasma were measured by sandwich ELISA using mAb r8B5.2 as
capture antibody, and mAb 10G1.5 (anti-total apoA125) as detecting antibody. To examine
the role of hepatocyte ABCA1 in de novo HDL biogenesis in vivo following apoA1
injection, WT fl/fl and hepatocyte-specific ABCA1-KO mice (6–7 weeks old) were injected
with the indicated apoA1 forms s.c. at 400 mg kg−1. Blood was collected by saphenous vein
puncture one week prior to apoA1 injection (baseline) as well as 0.5h, 1h, 1.5h and 2h post
apoA1 injection time. ApoA1-KO mice were similarly s.c. injected with the indicated apoA1
forms s.c. at 400 mg kg−1. and the appearance and distribution of total human apoA1 and
oxTrp72-apoA1 levels in blood monitored both at baseline and 2h post apoA1 injection time.
Statistical analysis—Data are presented as median (first quartile–third quartile) for
continuous measures and as number (percentage) for categorical measures. The Student’s ttest or Wilcoxon-Rank sum test for continuous variables and chi-square test for categorical
variables were used to examine the difference between participants who had cardiovascular
disease events and those who did not. Logistic regression models with adjustment for
traditional Framingham cardiac risk factors (age, sex, hypertension, diabetes mellitus,
current or former smoker, LDLc, HDLc), triglycerides (TG), apoA1, high sensitivity Creactive protein (hsCRP), MPO, hemoglobin A1C (HgbA1C) and history of lipid lowering
medicine were used to estimate odds ratio and 95% confidence interval for CVD or CAD.
All analyses were performed using R 2.15.0 (Vienna, Austria) and P-values <0.05 were
considered statistically significant.
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between wild type and affinity matured clones. (c) The increase in apparent affinity (KD) of
parental mAb 8B5.2 and affinity matured scFv r8B5.2 after conversion to full length mouse
and human chimeric IgG1, designated as r8B5.2. (d) mAb r8B5.2 recognizes with high
specificity only apoA1 or rHDL exposed to the MPO-H2O2-halide system, but not the
indicated alternative oxidation systems. ApoA1 or rHDL were coated onto 96 well plates
and detected with r8B5.2, as described in Methods. Data are mean± S.D. of triplicate
determinations.
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Figure 2. Epitope mapping of affinity matured mAb r8B5.2

(a) Antibody (r8B5.2) reactivity against the indicated recombinant human apoA1 (rhapoA1) and mutant forms was quantified before and following exposure to the MPO-H2O2halide system. The ELISA studies were performed as described in Methods and identify
oxidized Trp72 as a recognition epitope. (b) Total and ABCA1-dependent cholesterol efflux
activities in RAW macrophages were performed with rh-apoA1 and the indicated mutant
apoA1 forms before vs. following exposure to the MPO-H2O2-halide system, as described
under Methods. (c,d): Competition ELISAs. Purified human apoA1 oxidized by the
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MPO/H2O2/Cl− system served as coating antigen. Antibody r8B5.2 binding was competed
for with increasing concentrations of the various Trp-containing apoA1 competitor peptides
incorporating either native (non-oxidized) Trp or 2-OH-Trp at the indicated positions in c. In
d, either the peptide harboring native Trp, 2-OH-Trp or 5-OH-Trp corresponding to position
72 in the indicated apoA1 peptide sequence was used as the competitor. (e) Effect of Trp
substitutions on rh-apoA1 ABCA1-dependent cellular cholesterol efflux function. The
indicated rh-ApoA1 and mutant apoA1 proteins were exposed to the MPO/H2O2/Cl−
oxidation system at the specified molar ratios of H2O2/apoA1 (0 to 10:1, mol:mol). Proteins
were assayed for ABCA1-dependent cellular cholesterol acceptor activity as described in
Methods. All data shown are means ± S.D. of at least triplicate determinations.
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Figure 3. Characterization of oxTrp72-apoA1 recovered from human atherosclerotic plaque

(a) Immunohistochemical staining of fresh frozen normal and atherosclerotic sections of
human aorta. OxTrp72-apoA1 was detected with mAb r8B5.2. Mouse IgG was used as
control. Positive staining: Red; Blue, haematoxylin counter stain. (b) SDS-PAGE, protein
(SYPRO ruby) staining and (c) Western blot of human aortic plaque homogenate and the
indicated fractions separated by buoyant density ultracentrifugation. (d) Level of oxTrp72apoA1 (as a percentage relative to total apoA1) recovered in human aortic tissue
homogenate vs. the lipoprotein (d ≤ 1.21 g/ml) and lipoprotein depletion (LPD) fractions (d
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> 1.21 g/ml). N.A. = non-detectable. Means ± S.D. of triplicate determinations are shown.
(e) SDS-PAGE and Coomassie blue (protein) staining of mAb r8B5.2 immunopurified
oxTrp72-apoA1 from human aortic tissue (lane 2). As positive control, apoA1 exposed to the
MPO/H2O2/Cl− system (at 10:1 molar ratio of H2O2 to apoA1), Cl.apoA1, was loaded in
lane 4. ApoA1 monomer and dimer (MS sequence confirmed) are indicated. (f) ABCA1dependent cholesterol efflux activity of oxTrp72-apoA1 immunoaffinity purified from
individual human aortic plaque. Native apoA1 and Cl.apoA1 served as controls.
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Figure 4. Characterization of oxTrp72-apoA1 recovered from human plasma

(a) SDS-PAGE, Coomassie blue staining and (b) oxTrp72-apoA1 (mAb 8B5.2) western blot
of human plasma proteins before and after buoyant density ultracentrifugation separation
into the indicated fractions. (c) Distribution of oxTrp72-apoA1 in plasma. Results shown are
mean ± S.D. of triplicate determinations of four pooled healthy donor plasma pools. (d)
SDS-PAGE with Coomassie blue staining of immuno-purified (using mAb r8B5.2) oxTrp72apoA1 from plasma from four donors. (e) Bovine aortic endothelial cell (BAEC) were
incubated with aliquots of individual subjects’ plasma, total apoA1 (recovered using
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immobilized anti-total apoA1 IgY) or oxTrp72-apoA1 (using immobilized mAb r8B5.2) and
surface VCAM-1 protein expression was quantified by cell-based ELISA as described under
Methods. Serum free media (SFM), HDL, or HDL previously exposed to the MPO/H2O2/
Cl− system (Cl.HDL, at H2O2:apoA1, 10:1, mol mol) were used as vehicle, negative and
positive controls, respectively. *, P < 0.05. (f) Nuclear translocation of NF-κB: Confocal
immunofluorescent analysis of BAEC cells, untreated or treated with the following: IL-1
(positive control) native (apoA1) or MPO-oxidized human apoA1 (ox-apoA1), plasmaderived total apoA1 immunopurified using IgY to apoA1; plasma oxTrp72-apoA1 immunopurified using r8B5.2. NF-κB p65 (E498) staining is green and nuclear counterstaining
(DAPI) is blue. (g) Human apoA1-Tg mice were injected i.p. with zymosan (T=0). Plasma
oxTrp72-apoA1 levels were quantified at the indicated times by sandwich ELISA using mAb
r8B5.2 as capture antibody, and mAb 10G1.5 (anti-total apoA1) as detecting antibody, as
described in Methods.
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Figure 5. OxTrp72-apoA1 has impaired function in vivo and is associated with CVD

ApoA1 KO mice (6–8 weeks old) were injected s.c. with comparable amounts of apoA1 or
oxTrp72apoA1 as described in Methods. Total apoA1 levels (a), HDLc levels (b), and
apoA1 distribution within HDL or LPD fractions of plasma (c,d) were quantified at the
indicated times. In (e), plasma HDLc levels are shown from apoA1-KO mice injected s.c.
with equivalent amounts of either rh-apoA1, 72WF, or their corresponding MPO-oxidized
forms (formed at H2O2:apoA1, 10:1, mol:mol) beflore and 2h following apoa1 injections.
ApoA1 distribution within plasma HDL or LPD fractions (f) were also quantified pre-
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injection (0h) and 2h post injection. (g) Levels of oxTrp72-apoA1 (relative to total apoA1) in
plasma and human aortic plaque homogenate from the indicated number of subjects were
quantified by sandwich ELISA using mAb r8B5.2 as capture antibody and mAb 10G1.5
(anti-total apoA1) as detecting antibody. (h) Box whisker plots of oxTrp72-apoA1
concentration, and oxTrp72-apoA1/total apoA1 ratio (as percent) within plasma. (i) Odds
ratio and 95% confidence intervals for CVD risk (unadjusted and following multilogistic
regression analyses) are shown. The fully loaded model included oxTrp72-apoA1, apoA1,
age, sex, hypertension, diabetes, smoking, HDLc, LDLc, TG, hsCRP, HgbA1C, MPO and
lipid lowering medicine.
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Figure 6. Formation of a dysfunctional apoA1 form, oxTrp72-apoA1, within human
atherosclerotic lesions

(a) Schematic summary illustrating formation of an abundant dysfunctional apoA1 form in
human atheroma generated by MPO. (b) Model of spherical HDL demonstrating close
spatial proximity between MPO binding site on one apoA1 chain, and Trp72 on the
contralateral anti-parallel apoA1 chain. Shown are the longest (18Å) and shortest (6Å)
predicted distances among two of the three apoA1 chains43. The apoA1 polypeptide chains
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are depicted in red and slate gray. W72, yellow; MPO interaction site with apoA1, light
blue.
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